Tumors of the ocular surface have a wide clinical spectrum and include several forms of epithelial, stromal, caruncular, and secondary tumors [Table 1]. As a group, these tumors are seen commonly in the clinical practice of a comprehensive ophthalmologist, cornea specialist, and an ocular oncologist. This review is aimed to discuss the common tumors of the ocular surface, their clinical diagnosis, and management.
Epithelial Tumors of the Ocular Surface
Epithelial tumors of the ocular surface can be nonmelanocytic or melanocytic [Table 2].
Nonmelanocytic epithelial tumors
Squamous papilloma occurs in both children and adults with variable presentation. In children, it results from infection of the conjunctival epithelium with human papilloma virus (HPV) 6, 11 or 16. It could be solitary or multiple, and sessile or pedunculated. It becomes confluent in extreme cases to form massive papillomatosis. It appears most often as a pink or red mass with fleshy frond or finger-like projections in the inferior fornix, most common medially. It is also seen in bulbar conjunctiva but rarely in the cornea.
In adults, clinically, it may resemble squamous cell carcinoma (SCC). It may be associated with HPV infection and immunocompromised status. Usually, unilateral and solitary, it is seen at the limbus, encroaching the cornea as it grows. It can also arise in the caruncle. It has a lighter pink color than the childhood variety. Rarely, it can be pigmented particularly in those with dark skin. Squamous papilloma is reported to have low malignant potential. Occasionally, as a variant, it can assume an inverted growth pattern, which has a greater tendency towards malignant transformation into transitional cell carcinoma, SCC, or mucoepidermoid carcinoma. Histopathologically, the lesion shows numerous vascularized papillary fronds lined by acanthotic epithelium [Fig. 1].
Surgical excision by the “no-touch technique” followed by cryotherapy is the treatment of choice. Other reported treatment modalities include laser, dinitrochlorobenzene immunotherapy, interferon alpha 2b (IFN α-2b), and topical mitomycin C (MMC) drops. Recent reports show significant role of oral cimetidine in treating recalcitrant and recurrent conjunctival papillomatosis. It enhances the immune system by inhibiting certain T-cell functions.
The papilloma may invaginate inward into the underlying conjunctiva and substantia propria to present as a mixed inverted exophytic papilloma. Rarely, it appears as solid or cystic solitary nodule at the limbus, plica semilunaris, and tarsal conjunctiva. Treatment is by local excision.
Conjunctival pseudoepitheliomatous hyperplasia
It is a benign reactive inflammatory proliferation of the epithelial cells, which simulates carcinoma clinically and histopathologically. It occurs as a conjunctival lesion secondary to irritation by concurrent or preexisting stromal inflammation such as pterygium, pinguecula, allergic conjunctivitis, and foreign body. It appears as an elevated leukoplakic pink lesion in the limbal area [Fig. 2]. Histopathologically, it is characterized by massive acanthosis, hyperkeratosis, and parakeratosis of the conjunctival epithelium. Complete excision and additional cryotherapy would constitute optimal management, as difficulty prevails in clinically and histologically differentiating the lesion from low-grade SCC.
It is a variant of conjunctival pseudoepitheliomatous hyperplasia. Though it is a benign lesion, some believe that it may represent an abortive malignancy that rarely progresses to SCC. An elevated mass with hyperkeratosis or leukoplakia is the usual presentation. Onset as well as the progression is rapid. Treatment is by complete excision and cryotherapy.
Dacryoadenoma is a rare condition affecting children and young adults. It appears as a translucent and fleshy pink lesion in the bulbar, forniceal or palpebral conjunctiva. It arises from the surface epithelium and proliferates inward into the stroma and develops glandular lobules similar to those seen in normal lacrimal glands but with abundant goblet cells. Complete excision is the treatment of choice.
Conjunctival epithelial cyst
Conjunctival epithelial cyst can be congenital or acquired. There are two subtypes-inclusion cysts and ductal cysts. Inclusion cysts are further classified as spontaneous or posttraumatic. These cysts typically are smooth translucent lesions containing clear fluid. The contents may be turbid, containing epithelial debris seen layered like pseudohypopyon [Fig. 2]. Ductal cysts are lined by two layers of the epithelium and may contain secretory material. The cysts may remain stable and asymptomatic, and rarely undergo spontaneous resolution. Excision is the treatment of choice for a cyst that enlarges or becomes symptomatic.
Hereditary benign intraepithelial dyskeratosis
This is a rare autosomal dominant condition of the conjunctiva and other mucous membranes. It is specifically seen among the inbred Caucasians, African-Americans, and Native Americans known as Haliwa Indians but, is also seen in the population of other descent. The lesion generally presents in the first decade of life as an elevated hyperemic and fleshy V-shaped plaque on the nasal and temporal bulbar conjunctiva and limbus [Fig. 3]. It may be asymptomatic or, can cause redness and discomfort. Severe form can lead to corneal vascularization, opacification, and loss of vision. Smaller symptomatic lesions are treated conservatively with lubricants and topical steroids while larger lesions undergo local resection with ocular surface reconstruction. It carries no risk of malignancy, but recurrence is common. Hence, complete excision with clear margins is warranted. Histopathologically, there is marked acanthosis and hyperkeratosis of the conjunctival epithelium with prominent dyskeratosis.
Conjunctival keratotic plaque
This leukoplakic lesion that may develop in the bulbar conjunctiva is usually in the interpalpebral region. There is thickening and keratinization of conjunctival epithelium characterized mainly by acanthosis, hyperkeratosis, and parakeratosis. Dyskeratosis is always absent. It has little or no malignant potential.
Seen commonly as a focal leukoplakic lesion occurring at the interpalpebral area presenting as flat, white plaque sometimes with a frothy covering, actinic keratosis progresses very gradually and shows no tendency towards aggressive growth. Clinically, it may often be indistinguishable from conjunctival intraepithelial neoplasia (CIN) [Fig. 4]. Rose bengal staining of the surface of the lesion tips the clinical suspicion in favor of CIN. Actinic keratosis is a relative indication for surgical excision and supplemental cryotherapy. Close observation of the lesion until progression is documented is a reasonable option.
Ocular surface squamous neoplasia
Ocular surface squamous neoplasia (OSSN) is an encompassing term for precancerous and cancerous epithelial lesions of the conjunctiva and cornea. It includes the spectrum of dysplasia, CIN, and invasive SCC. Previously used terms for this condition include intraepithelial epithelioma, Bowens disease, and Bowenoid epithelioma. CIN accounts for 39% of all premalignant and malignant lesions of the conjunctiva and for 4% of all conjunctival lesions. Unlike CIN, incidence of invasive SCC is of much lesser frequency, varying from 0.02 to 3.5/100,000 population. About 75% occur in men, 75% are diagnosed in older patients and over 75% occur at the limbus. Factors associated with the development of OSSN are exposure to sunlight, HPV type 16 infections, and immunocompromised status. Studies have shown interaction of AIDS with ultraviolet-induced damage and HPV infection. Systemic associations of the development of OSSN include xeroderma pigmentosum and Papillon-Leferve syndrome.
Ocular surface squamous neoplasia is mostly unilateral and is seen in middle-aged and older patients. Rarely, it is bilateral in immunosuppressed patients. It often presents with redness and ocular irritation. Vision is usually unaffected unless it encroaches the center of the cornea. The tumor appears as fleshy or nodular, sessile minimally elevated lesion with surface keratin, feeder vessels, and secondary inflammation. Rose bengal staining is helpful in the diagnosis and delineation of the tumor extent [Fig. 5d]. The tumor may extend for a variable distance into the adjacent corneal epithelium and appear as a subtle wavy, advancing, gray, superficial opacity that may be relatively avascular or may have fine blood vessels. Whereas some lesions may present as diffuse gelatinous or papilliform form usually encroaching the cornea [Fig. 5]. Primary corneal dysplasia affects the corneal epithelium with minimal limbal involvement. Primary SCC of the cornea is rare.
There are no consistent clinical criteria for distinguishing CIN from invasive SCC. Leukoplakia is usually absent or minimal in CIN; extensive leukoplakia raises the suspicion of malignancy. The presence of feeder vessels and intrinsic vascularity favors SCC. Although greater thickness is believed to be a sign of malignant transformation, there are thick tumors that remain within the epithelium. The nodular lesion causes suspicion of invasive SCC. A diffuse lesion can masquerade as chronic conjunctivitis [Table 3]. It is also important to examine the tarsal conjunctiva after everting the eyelid of patients with OSSN to detect contiguous or multifocal involvement of the tarsal conjunctiva.
Advanced cases can infiltrate the cornea and sclera to have the intraocular extension. Rarely, the tumor may extend into the orbit causing proptosis. The tumor can metastasize to the regional lymph nodes and rarely distant metastasis may occur. Aggressive variants include spindle cell squamous carcinoma, mucoepidermoid carcinoma, and adenoid SCC. According to the American Joint Committee on Cancer (AJCC)-tumor, node, and metastasis (TNM) classification, SCC is classified depending on the size, tumor location, and extent of involvement [Table 4].
Histopathologically, mild CIN (dysplasia) is characterized by partial thickness replacement of the epithelium by anaplastic cells that lack normal maturation. Severe CIN is characterized by full thickness replacement of the epithelium by similar cells. Both the variants show a characteristic abrupt demarcation between affected epithelium and normal epithelium. Invasive SCC shows a breach in the basement membrane of basal epithelium and is typically a fairly well-differentiated neoplasm composed of abnormal epithelial cells with mitotic activity and keratin. Occasionally, it can be poorly differentiated and shows bizarre, pleomorphic cells, numerous mitotic figures, acanthosis, and dyskeratosis [Fig. 6].
Complete but gentle surgical excision using a technique without touching the tumor called the “no-touch” technique [Table 5] is the treatment of choice. The steps of surgical excision include:
- Conjunctival incision is made approximately 4 mm outside the clinically determined tumor margin. The incision incorporates full thickness conjunctiva and tenon's fascia
- Dissection is carried out in the episcleral plane (if there is no episcleral adhesion) to reach the limbus
- Thin lamellae of the tumor-free sclera, 0.2 mm in depth including 2.0 mm outside the adherent conjunctival mass are removed if scleral fixity is noted
- Absolute alcohol is applied with cotton-tipped applicator to the involved cornea to allow for controlled corneal epitheliectomy 2 mm outside the corneal component
- The corneal epithelium is scrolled off to the limbus using a controlled sweeping motion with a beaver blade
- The entire tumor is removed in one piece without touching the tumor by excising it along the limbus
- Cryotherapy, double freeze-thaw cycle, is applied to the edge of the remaining bulbar conjunctiva and the scleral base if there was episcleral adhesion. Limbal cryotherapy should be limited to 6 clock hours
- Excision is followed by direct closure of the conjunctiva or with amniotic membrane graft [Fig. 7].
Reported recurrence rate of OSSN is 15–52%. Lee and Hirst reported a 17% recurrence after excision of conjunctival dysplasia, 40% after excision of CIN and 30% for SCC of the conjunctiva. However, with the protocol-based technique as described above, the recurrence rate can be limited to <5%.
Plaque brachytherapy is used to control gross or microscopic residual tumors. More extensive orbital invasion requires orbital exenteration.
Conjunctival intraepithelial neoplasia and mild forms of SCC can be treated with topical MMC 0.02–0.04% [Tables 6 and 7]. There are several protocols [Table 6] but a dosage of 0.04%, qid, 4-days-a-week for 4 weeks works best in our experience. Associated local complications include conjunctival hyperemia, punctate corneal erosions, and inadvertent prolonged use may lead to scleral melt. Interferon alpha 2b is currently most accepted and favorable form of treatment for OSSN. It is less toxic with fewer complications compared to topical MMC. Their beneficial role includes immunomodulation, anti-proliferative, and anti-viral. The reported success rate is 83% with topical IFN 1 million IU administered 4 times daily for 6–12 months. Intralesional injection of IFN α-2b of 3 million IU to 10 million IU combined with 1 million IU topical IFN is widely used as a primary modality (immunotherapy) for unresectable extensive tumors. It also helps in reducing the tumor size (immunoreduction), ideally followed by complete excision of the residual tumor. Similarly it plays a major role in immunosuppressed patients with OSSN, with a high rate of recurrence. The long-term use of topical IFN helps to prevent recurrence by way of immunomodulation. The most common complication is transient flu-like syndrome, whereas local complications are minimal [Table 8]. Other available drugs are 5-fluorouracil and cidofovir.
Ocular surface squamous neoplasia has a good prognosis. With the modern techniques, the local recurrence rate is about 5% and regional metastasis of 2%. Prognosis is worse in mucoepidermoid or spindle cell variants and in immunosuppressed patients.
Melanocytic Epithelial Tumors
Conjunctival melanocytic nevus
Melanocytic tumors of the conjunctiva have a wide spectrum [Table 9]. Conjunctival nevus usually becomes apparent in the first to the second decade of life as a group of small nests of pigmented epithelial cells in the basal layer of the epithelium. As the cells migrate into the underlying stroma in the second to third decade, the nevus progresses to become the compound nevus. Further migration occurs, and cells reside in the stroma as sub-epithelial nevus during the third and fourth decades. Nevus is more commonly seen in Caucasians (89%) than Africans (6%) and Asians (5%). Although most conjunctival nevi are pigmented (84%), some may be amelanotic or partially pigmented (16%).
Conjunctival nevi are mostly located near the limbus in the interpalpebral area (72%). Other locations are the caruncle, semilunar folds, fornix, tarsus, and cornea. Characteristic clear cysts strongly support the diagnosis. They may also clinically demonstrate feeder vessels (64%) and intrinsic vascularity (77%). [Fig. 8a] It can vary in size, color, and location. Conjunctival nevus can increase in size in growing young children, during puberty, pregnancy, and sun exposure. Malignant transformation was estimated to be <1%. Sudden increase in size, alteration in color, and increased thickness with prominent feeder vessels indicates malignant transformation. Irregular and diffuse growth pattern poses a diagnostic confusion with primary acquired melanosis (PAM), melanoma, lymphoma, and pigmented OSSN. Histopathologically, a conjunctival nevus is composed of nests of benign melanocytes in the stroma near the basal layers of the epithelium [Fig. 8b]. Positive immunostaining for HMB-45 and Ki-67 are useful adjuncts in differentiating benign melanocytic lesion from suspected malignant entities.
Periodic (annual) observation with slit lamp measurements and serial photographs is the management of choice. If excision is performed for cosmesis or suspected growth, it is preferable not to leave any residual lesion [Table 10].
Ocular melanocytosis is a congenital pigmentary condition of the periocular skin, sclera, orbit, meninges, and soft palate. It appears as irregular patches of scleral and episcleral pigmentation varying in color from brown to gray [Fig. 9]. Typically, there is no conjunctival pigment. It can involve the underlying uveal tract. Since it is episcleral involvement, it does not move with manipulation of the conjunctiva. This condition imparts a 1 in 400 risk for the development of uveal melanoma.
If associated with the dermal component, it is known as oculodermal melanocytosis or nevus of Ota [Fig. 7b and c]. It is mandatory that all patients with oculodermal melanocytosis undergo fundus examination to exclude uveal melanocytosis or melanoma. Associated hairline pigmentation predisposes them for meningeal melanoma and palate pigmentation to esophageal melanoma, therefore, these signs should be elicited with appropriate referrals when needed.
Complexion-related conjunctival pigmentation
Complex-related conjunctival pigmentation is a relatively common bilateral, flat, diffuse conjunctival pigmentation. It is more concentrated in the limbus, often for 360°, with variable pigmentation at the perilimbal bulbar conjunctiva and cornea [Fig. 8]. Uncommonly, it may also involve the fornix and rarely the palpebral conjunctiva. Periodic observation is recommended.
Primary acquired melanosis
Reese noted the tendency of a certain type of acquired conjunctival pigmentation to evolve into melanoma and named it precancerous melanosis. Zimmerman replaced the term with benign acquired melanosis, which was further modified by WHO as PAM in 1980.
Sunlight exposure may play a role in the development of PAM. It has also been seen in patients with neurofibromatosis raising suspicion that it may have a developmental relationship to the neural crest.
Primary acquired melanosis usually manifests in the middle age as unilateral, superficial, solitary, patchy, diffuse or multifocal pigmentation of the bulbar, fornicial and palpebral conjunctiva, and cornea [Fig. 10a]. Occasionally PAM can be amelanotic. In PAM without atypia, there occurs melanin pigmentation of the basal epithelium with or without hyperplasia of cytological benign melanocytes. This may progress to cytological atypical melanocytes to form PAM with atypia, where there is an increased risk of developing melanoma [Fig. 10b]. Studies show that among those with atypia, 13% develop melanoma.
Clinically, larger the extent of PAM, greater the risk of malignant transformation.
Management strategies are [Table 11]:
- Observation for PAM without atypia
- Cryotherapy for PAM with atypia <3 clock hours
- Excision with excision edge cryotherapy for PAM >3 clock hours
- Topical MMC for diffuse PAM with atypia.
Conjunctival melanoma is most common in light-skinned individuals. It usually presents in the middle-aged or elderly. It has no predilection for gender. It arises from PAM in about 75%, preexisting nevus in 20%, and de-novo in 5%. Other risk factors are dysplastic nevus syndrome, neurofibromatosis, and xeroderma pigmentosum. Sunlight exposure is also suggested as a cause, but that fails to explain the occurrence of melanoma in the fornices and palpebral conjunctiva.
Conjunctival melanoma appears as a pigmented fleshy mass located in the bulbar, fornicial or palpebral conjunctiva [Fig. 11a]. As a variant, it may appear as diffuse or multifocal with ill-defined margins particularly if arising from PAM. It occasionally originates in the forniceal and palpebral conjunctiva. It may extend to cover the cornea or even arise as a primary corneal tumor. Conjunctival melanoma may rarely develop secondary to continuous touch from an eyelid margin melanoma (implantation melanoma). Melanoma can be sparsely pigmented or amelanotic. It is typically amelanotic, fleshy, and vascular when it recurs after prior excision. Conjunctival melanoma is classified according to the AJCC-TNM classification [Table 12].
Regional metastasis involves preauricular and submandibular lymph nodes. Sentinel lymphangiography makes it possible to accurately remove lymph nodes and is indicated in tumors more than 2 mm thickness. Distant metastasis occurs in the brain, liver, skin, and bone.
Histopathologically, conjunctival melanoma is composed of variably pigmented malignant melanocytes [Fig. 11b]. These cells are positive for S-100 protein, tyrosinase, melan-A, HMB-45, HMB-50, and microphthalmia conscription factor [Table 12].
Treatment of conjunctival melanoma is based on certain established principles:
- Complete excision in the episcleral plane with 4 mm clinically clear margins
- Alcohol keratoepitheliectomy of the corneal epithelial component
- Partial lamellar sclerokeratectomy if sclera or corneal stroma are involved
- Double freeze-thaw cryotherapy to the excision edge, excision base cryotherapy if sclera is involved and the extent of involvement is <3 clock hours
- Postoperative adjuvant plaque brachytherapy if excision base is clinically detected to have been involved >3 clock hours and if the excision base is positive for tumor cells on histopathology. Since conjunctival melanoma is not radiosensitive, brachytherapy is not used as a sole treatment
- Extended enucleation with en-bloc excision if the tumor has deep corneal or sclera invasion or intraocular extension
- Eyelid sparing exenteration if the tumor extends into the orbit. Proton beam radiotherapy may be used as an alternative and/or adjunct to exenteration
- Systemic chemotherapy is administered with combination of IFN and interleukin-2 in disseminated melanoma.
Local recurrence after therapy is as high as 50–70% at 10 years. Overall mortality rate is 25% in 10 years and more than 30% in 15 years. Critical thickness that may serve as a prognostic factor, according to various studies implies a value between 0.8 and 4 mm. Conjunctival melanoma AJCC-TNM staging predicts the prognosis and outcome [Table 12].
Stromal Tumors of the Ocular Surface
Vascular stromal tumors
Pyogenic granuloma is a misnomer; it is neither pyogenic nor a granuloma, but exhuberant granulation tissue. It is a fibrovascular response to a tissue insult such as surgical or nonsurgical trauma or inflammation. It has rapid onset and progression and presents as fleshy, elevated, red, richly vascular mass [Fig. 12a]. It can be round to ovoid, typically pedunculated, rarely broad-based, and even mushroom shaped. It may be seen in any part of the conjunctiva, limbus, and the cornea. Histopathologically, it is composed of granulation tissue with lymphocytes, plasma cells, scattered neutrophils, and numerous small caliber vessels.
- Often responds to topical steroids when diagnosed early
- Excision at the base followed by cauterization or cryotherapy to the excision base is the treatment of choice for larger, unsightly, symptomatic or bleeding pyogenic granuloma
- Along with excision, it is optimal to take care of the inciting factor if found to minimize the risk of recurrence. It is usual to find a suture knot or a foreign body at the base if the cause is prior surgery or trauma
- Exuberant recurrence can be treated with low dose plaque brachytherapy.
Capillary hemangioma is common in the eyelids but is less common in the orbit and uncommon in the conjunctiva [Fig. 12b]. Seen as diffuse red elevated lesion, it may present as a small conjunctival component of a predominant eyelid lesion in a neonate. It may uncommonly develop as an acquired lesion in adults.
It presents at birth along with the lid lesion involving the conjunctiva, growing over the initial several months and then regresses spontaneously over several years. Spontaneous regression is often complete by 4–5 years of age. Histologically, it is composed of lobules of proliferating endothelial cells separated by thin fibrous septa.
Management generally is observation until spontaneous regression. Intervention is indicated if the concurrent eyelid component is amblyogenic-is large enough to induce mechanical ptosis or astigmatism. Intervention is also considered if the lesion is unsightly, ulcerates and bleeds and relentlessly progresses. Typical primary intervention is intralesional steroid injection. Triamcinolone is used in the maximum dose of 6 mg/kg body weight. In general, one injection results in significant involution of the lesion. Injection may be repeated at 6–8 weeks interval if there is a suboptimal response. Dermatologists favor using high-dose oral steroids over 4–6 weeks. Systemic propranolol 2 mg/kg body weight is being tried as an alternative therapy with encouraging results. If the tumor does not respond to these measures or if there is an indication for an emergent management (as in ulcerated and bleeding lesions), controlled surgical excision or debulking may help.
Cavernous hemangioma is a common orbital tumor, but relatively uncommon in the conjunctiva. It appears as red blue lesion in the deep conjunctival stroma. Histology shows dilated congested veins separated by connective tissue with smooth muscles in the walls of the blood vessels. Treatment is by surgical excision.
Varix refers to venous malformation of the conjunctiva that may range from an isolated single channel to dilated complex venous channels [Fig. 12c]. Often, it is the anterior extension of an orbital varix. Management is generally conservative by observation and symptomatic treatment.
Racemose hemangioma involves loops of dilated arteries and veins communicating directly without the interface of a capillary bed. The lesion is clinically seen as loops of dilated vessels in the conjunctival stroma with no evidence of a stimulus for such vascularization or planned direction. It may be associated with Wyburn-Mason syndrome. It is generally observed unless symptomatic or a cosmetic blemish.
Hemangiopericytoma is known to be derived from the vascular pericytes but is recently considered to be a vascular entity of the solitary fibrous tumor. It is a very rare conjunctival tumor that presents as an elevated or pedunculated red mass, which is slowly progressive. A wide surgical resection with tumor-free margins is advocated.
Kaposi sarcoma was a rare tumor before the AIDS era. It is a malignant tumor seen more frequently in immunocompromised individuals, specifically with HIV infection. Sometimes the conjunctival Kaposi sarcoma is the first sign of immunocompromised status. It clinically appears as single or multifocal vascular red conjunctival lesion, which may become confluent and resemble hemorrhagic conjunctivitis.
- It is moderately responsive to IFN α-2a and chemotherapy and markedly responsive to low dose radiotherapy (800–2000 cGy)
- The current thinking is in favor of the immediate institution of highly active antiretroviral therapy. The tumor is known to involute with improved immune status.
When lymphatic channels in the conjunctiva are dilated and prominent, the condition is called lymphangiectasia. There exists a communication with conjunctival veins, and hence these dilated channels may often be filled with blood, termed hemorrhagic lymphangiectasia. Surrounding conjunctiva appears edematous and is occasionally associated with sub-conjunctival hemorrhage. It can occur spontaneously or after trauma or inflammation. It is intermittent with a resolution between episodes. No treatment is required unless it is a cosmetic blemish, and the patient is keen on excision.
Lymphangioma is a benign tumor of the lymphatic vessels that usually manifests in the first decade of life. It can occur as an isolated conjunctival lesion, but often represents a superficial component of an orbital lymphangioma. These are multiloculated lesions with dilated cystic spaces. Those that contain blood are called chocolate cysts [Fig. 12d].
It histopathologically appears as nonencapsulated, irregular mass composed of numerous cyst-like channels that contain clear fluid, blood, or a combination of the two. The ectatic channels are lined by somewhat attenuated endothelial cells. These channels are separated by loose connective tissue that contains aggregates of small lymphocytes, sometimes forming lymph follicle.
- Surgical debulking
- CO2 laser-assisted debulking
- β-irradiation using strontium-90 applicator
- Brachytherapy is used with partial success.
They are of three major types of conjunctival lymphoproliferative lesions, varying from benign to malignant and present as a spectrum, but may appear identical clinically:
- Reactive lymphoid hyperplasia
- Atypical lymphoid hyperplasia
- Conjunctival lymphoma.
There is increasing emphasis that many conjunctival lymphomas may be low-grade B-cell lymphomas of the mucosa-associated lymphoid tissue type. In a third of patients, conjunctival lymphoma manifests with coexisting systemic lymphoma. Patients usually present with a conjunctival mass. They may also present with nonspecific irritation, ptosis, epiphora, blurred vision, proptosis, and diplopia.
Conjunctival lymphoproliferative lesions appear as diffuse, slightly elevated pink mass, resembling smoked salmon. Seen mostly in the bulbar conjunctiva and fornix [Fig. 13a]. Some appear in the caruncle and plica, but very rarely in the palpebral conjunctiva. In the unilateral cases chance of systemic lymphoma is 17%, and if bilateral the chance is 47%. Systemic lymphoma occurs in 15% of patients at 5 years and 28% in 10 years.
Histopathologically, conjunctival lymphoproliferative tumors are composed of solid sheets of lymphocytes, with overlap between benign reactive lymphoid hyperplasia, atypical lymphoid hyperplasia, and malignant lymphoma [Fig. 13b]. Benign reactive lymphoid hyperplasia is generally polymorphic, with well-differentiated lymphocytes and plasma cells, while lymphoma tends to be more monomorphic and poorly differentiated. Most are non-Hodgkin's B-cell lymphomas whereas Hodgkins and T-cell lymphoma affect the conjunctiva rarely. Immunohistochemistry may be helpful in determining the cell types.
Prognostic factors for developing systemic lymphoma are fornicial or mid-bulbar location, multifocality, and bilaterality. There are several treatment options.
- Excision biopsy
- Low-dose external beam radiotherapy
- Local injection of IFN α
- Chemotherapy if associated with systemic involvement.
Fibrous tumors manifest generally as slowly progressive acquired white stromal tumors in adults. These could be a well-circumscribed lesion or multi-nodular. Common fibrous tumors affecting the ocular surface are fibrous histiocytoma and nodular fasciitis.
It can be benign, locally aggressive, and malignant, seen in adults. Presents commonly as well-circumscribed to diffuse amelanotic mass, often in the limbus and frequently extends to involve the cornea. Seen deep in the conjunctiva and attached to the sclera. It has yellow color owing to the presence of histiocytes. Malignant transformation is extremely rare. Benign fibrous histiocytoma is completely excised while malignant fibrous histiocytoma may need radical excision with clear margins.
Nodular Fasciitis (Pseudosarcomatous Fasciitis)
It is thought to arise from the tenon's capsule. It presents in the varied age group ranging from 3 to 81 years as a solitary white episcleral enlarging nodule at the limbus or over the sclera anterior to the insertion of one of the rectus muscle. The nodule may grow quickly and show signs of inflammation. Treatment is by complete surgical excision.
Simple neuroma is soft mucosal neural tumors that appear in the conjunctiva and other mucous membrane in patients with MEN-2b. All such patients have prominent corneal nerves. Clinically, these lesions appear as pink-yellow and grow over time. There is significant association with medullary carcinoma of the thyroid.
Schwannoma of the ocular surface are rare and can occur in any part of the conjunctiva. These present as pink or yellow elevated slow-growing lesion and may have mildly dilated conjunctival or episcleral nutrient vessels. Treatment is by complete excision along with the tumor capsule.
Granular Cell Tumor
Granular cell tumor, also known as myoblastoma, is extremely rare. Originally thought of having a striated muscle origin, recent suggestions are that it is of neural derivative, Schwann cell origin. It is seen as a pink elevated smooth mass of the conjunctival stroma. Pseudoepitheliomatous hyperplasia of the overlying conjunctival epithelium is a recognized feature of this tumor. Treatment is by complete excision.
Xanthoma presents as a yellow subepithelial mass on the epibulbar surface. In xanthoma disseminatum, multiple limbal lesions are found in both the eyes.
Xanthogranuloma occurs as a solitary orange-pink stromal mass usually near the limbus in adults. There are isolated case reports of juvenile xanthogranuloma of the conjunctiva in children. Histopathologically, histiocytes admixed with Touton's giant cell confirms the diagnosis. It is managed by observation for spontaneous resolution, topical or systemic steroids for cases that do not resolve, and excision in recurrent cases.
Reticulohistiocytoma is a benign conjunctival lesion that is often a part of the systemic disorder known as multicentric reticulohistiocytosis. It appears as a single painless mass localized to the cornea and limbus with evidence of systemic disease. Treatment is by complete excision.
Myxoid tumors are rare benign stromal tumors, manifesting as slowly growing, asymptomatic freely movable unilateral, soft, pink white lesions usually seen in the temporal bulbar conjunctiva. These can be associated with Carney complex. The presence of these lesions should prompt the evaluation of cardiac myxoma-a life-threatening condition. Histologically, they are hypocellular and are composed of stellate and spindle-shaped cells interspersed in the loose stroma.
The occurrence of rhabdomyosarcoma in the conjunctiva alone is rare - it generally has an orbital component. Most commonly the embryonal type manifests with a conjunctival component Botryoid rhabdomyosarcoma may be seen in the conjunctival fornices. Rhabdomyosarcoma presents as a pink, rapidly growing vascular conjunctival mass [Fig. 14]. It may appear as a pedunculated soft tissue mass but occasionally swelling and erythema precede the visible tumor. Complete surgical excision with protocol-based adjuvant chemotherapy and radiotherapy is the treatment of choice for rhabdomyosarcoma localized to the conjunctiva.
Lipoma and liposarcoma
Lipoma is usually seen in adults. It appears as yellow pink stromal mass. Liposarcoma is clinically similar to lipoma but histopathology reveals neoplastic stellate lipid cells and signet ring cells have been observed.
Choristoma is a congenital lesion representing the excess of normal tissue in an abnormal location. It is considered a simple choristoma when composed of one type of tissue and a complex choristoma when a combination of displaced tissue is involved. Epibulbar choristomas are generally found in children, dermoid and dermolipoma being most common. Usual locations are cornea, limbus, and episclera. Epibulbar choristomas can be associated with eyelid and uveal coloboma, Goldenhar syndrome or organoid nevus syndrome [Fig. 15a].
Epibulbar dermoid is a well-circumscribed yellow white solid lesion involving the corneoscleral limbus. It most commonly occurs at the inferotemporal limbus and has fine white hairs that are best seen with slit lamp biomicroscopy [Fig. 15b and c]. It is not uncommon to see them associated with Goldenhar syndrome [Fig. 15a]. Rarely, it can extend to the central cornea or be located in the other quadrants. In addition to becoming a cosmetic blemish, can cause severe astigmatism and amblyopia in some cases. Histopathologically, epibulbar dermoid is a simple choristomatous malformation that consists of dense fibrous tissue lined by conjunctival epithelium with deeper dermal elements including hair follicles and sebaceous glands [Fig. 15d].
Observation alone is preferred if the dermoid is small and does not cause visual symptoms. Larger demoids can be excised by lamellar keratosclerectomy with amniotic membrane grafting if the defect is superficial or closure using lamellar or full thickness corneal or sclerocorneal graft if the defect is deep or full thickness. While the cosmetic appearance does improve with surgery, the astigmatic error and visual acuity may not change significantly unless the child is treated early.
Although dermolipoma is congenital and present at birth, it typically remains asymptomatic for years and may not be detected until adulthood. The lesion presents as a pale yellow, soft, fluctuant, mass protruding from the orbit through the conjunctival fornix superotemporally [Fig. 15c]. Unlike herniated orbital fat, dermolipoma may show the fine white hair on its surface. Histopathologically, it is lined by conjunctival epithelium on its surface, and sub-epithelial tissue has variable quantities of collagenous connective tissue and adipose elements. Pilosebaceous units and lacrimal gland tissue may occasionally be present.
No treatment is required unless for cosmetic considerations or in symptomatic patients with exuberant hair growth over the lesion. Visible portion of the dermolipoma may be debulked, and the ocular surface reconstructed with amniotic membrane graft.
Caruncular Tumors and Cysts
The caruncle is a unique anatomic structure containing elements of both conjunctiva and skin. The lesions occurring in the caruncle are similar to those that occur in mucous membranes and cutaneous structures. By histopathological analysis, 95% of the caruncular lesions are benign, and 5% are malignant. The most common lesions in the caruncle include papilloma and nevus. [Fig. 16a] Other lesions of caruncle include pyogenic granuloma, inclusion cysts, sebaceous hyperplasia, sebaceous adenoma, and oncocytoma. Oncocytoma is a benign tumor that occurs more commonly in the lacrimal or salivary glands. It probably arises from the accessory lacrimal gland tissue in the caruncle. Malignant tumors occurring rarely in the caruncle are SCC, melanoma, lymphoma, and sebaceous carcinoma. [Fig. 16a and b] Treatment includes either observation or local resection, depending upon the diagnosis.
Metastatic and Secondary Tumors
Metastatic tumors are rare, but conjunctival metastasis can occur from breast carcinoma, cutaneous melanoma, or other primary tumors. They appear as one or more fleshy pink vascularised conjunctival stromal tumors. Metastatic melanoma to the conjunctiva is usually pigmented.
Conjunctival leukemic infiltrate is associated with acute myeloid leukemia. It is often an early sign of relapse of previously treated disease. It may be unilateral or bilateral with focal or diffuse lesions in the bulbar or palpebral conjunctiva. It has a spectrum of presentation, ranging from subconjunctival hemorrhage to direct infiltration of the tissue with leukemic cells but often manifests as a firm, nontender, pink smooth mass associated with hemorrhage. It has the tendency to appear in the perilimbal tissue near the cornea.
The conjunctiva can be secondarily involved by tumors of adjacent structures, particularly by direct extension from the tumor of the eyelid. Intraocular and orbital tumors may also extend into the conjunctiva. Most important is the sebaceous gland carcinoma of the eyelid which can exhibit pagetoid invasion and direct invasion into the conjunctival epithelium. Uveal melanoma can extend extrasclerally into the subconjunctival tissues. Rhabdomyosarcoma of the orbit in children occasionally presents first with its conjunctival component.
Tumors of the ocular surface have a wide clinical spectrum. It is possible to make an accurate clinical diagnosis in most cases. Benign tumors and choristomas are excised only if there is a cosmetic or functional concern. Malignant tumors generally need complete excision with clear margins and excision edge cryotherapy. Prognosis for local tumor control is excellent with protocol-based management.
1. Shields CL, Shields JA. Tumors of the conjunctiva and cornea Surv Ophthalmol. 2004;49:3–24
2. Shields JA, Shields CL. Eyelid, Conjunctival and Orbital Tumors An Atlas and Textbook. 20082nd ed Philadelphia, PA Lippincott Williams and Wilkins:250–445
3. Lass JH, Jenson AB, Papale JJ, Albert DM. Papillomavirus in human conjunctival papillomas Am J Ophthalmol. 1983;95:364–8
4. Lass JH, Grove AS, Papale JJ, Albert DM, Jenson AB, Lancaster WD. Detection of human papillomavirus DNA sequences in conjunctival papilloma Am J Ophthalmol. 1983;96:670–4
5. Kremer I, Sandbank J, Weinberger D, Rotem A, Shapiro A. Pigmented epithelial tumours of the conjunctiva Br J Ophthalmol. 1992;76:294–6
6. Streeten BW, Carrillo R, Jamison R, Brownstein S, Font RL, Zimmerman LE. Inverted papilloma of the conjunctiva Am J Ophthalmol. 1979;88:1062–6
7. Jakobiec FA, Harrison W, Aronian D. Inverted mucoepidermoid papillomas of the epibulbar conjunctiva Ophthalmology. 1987;94:283–7
8. Harkey ME, Metz HS. Cryotherapy of conjunctival papillomata Am J Ophthalmol. 1968;66:872–4
9. Bosniak SL, Novick NL, Sachs ME. Treatment of recurrent squamous papillomata of the conjunctiva by carbon dioxide laser vaporization Ophthalmology. 1986;93:1078–82
10. Jackson WB, Beraja R, Codère F. Laser therapy of conjunctival papillomas Can J Ophthalmol. 1987;22:45–7
11. Petrelli R, Cotlier E, Robins S, Stoessel K. Dinitrochlorobenzene immunotherapy of recurrent squamous papilloma of the conjunctiva Ophthalmology. 1981;88:1221–5
12. Lass JH, Foster CS, Grove AS, Rubenfeld M, Lusk RP, Jenson AB, et al Interferon-alpha therapy of recurrent conjunctival papillomas Am J Ophthalmol. 1987;103:294–301
13. Hawkins AS, Yu J, Hamming NA, Rubenstein JB. Treatment of recurrent conjunctival papillomatosis with mitomycin C Am J Ophthalmol. 1999;128:638–40
14. Shields CL, Lally MR, Singh AD, Shields JA, Nowinski T. Oral cimetidine (Tagamet) for recalcitrant, diffuse conjunctival papillomatosis Am J Ophthalmol. 1999;128:362–4
15. Streeten BW, Carrillo R, Jamison R, Brownstein S, Font RL, Zimmerman LE. Inverted papilloma of the conjunctiva Am J Ophthalmol. 1979;88:1062–6
16. Jakobiec FA, Harrison W, Aronian D. Inverted mucoepidermoid papillomas of the epibulbar conjunctiva Ophthalmology. 1987;94:283–7
17. Munro S, Brownstein S, Liddy B. Conjunctival keratoacanthoma Am J Ophthalmol. 1993;116:654–5
18. Schellini SA, Marques ME, Milanezi MF, Bacchi CE. Conjunctival keratoacanthoma Acta Ophthalmol Scand. 1997;75:335–7
19. Coupland SE, Heimann H, Kellner U, Bornfeld N, Foerster MH, Lee WR. Keratoacanthoma of the bulbar conjunctiva Br J Ophthalmol. 1998;82:586
20. Jakobiec FA, Perry HD, Harrison W, Krebs W. Dacryoadenoma. A unique tumor
of the conjunctival epithelium Ophthalmology. 1989;96:1014–20
21. Yanoff M. Hereditary benign intraepithelial dyskeratosis Arch Ophthalmol. 1968;79:291–3
22. Shields CL, Shields JA, Eagle RC Jr. Hereditary benign intraepithelial dyskeratosis Arch Ophthalmol. 1987;105:422–3
23. Mauriello JA Jr, Napolitano J, McLean I. Actinic keratosis and dysplasia of the conjunctiva: A clinicopathological study of 45 cases Can J Ophthalmol. 1995;30:312–6
24. Lee GA, Hirst LW. Ocular surface squamous neoplasia Surv Ophthalmol. 1995;39:429–50
25. Pe’er J. Ocular surface squamous neoplasia Ophthalmol Clin North Am. 2005;18:1–13, vii
26. Pizarello LD, Jakobeic FAJakobeic FA. Bowens disease of the conjunctiva: A misnomer Ocular and Adnexal Tumors. 1978 Brimingham, AL Aesculapius:553–71
27. Shields CL, Demirci H, Karatza E, Shields JA. Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors Ophthalmology. 2004;111:1747–54
28. Farah S, Baum TD, Conton MRAlbert DM, Jakobiec FA. Tumors of cornea and conjunctiva Principles and Practice of Ophthalmology. 20002nd ed Philadelphia WB Saunders:1002–19
29. Tunc M, Char DH, Crawford B, Miller T. Intraepithelial and invasive squamous cell carcinoma of the conjunctiva: Analysis of 60 cases Br J Ophthalmol. 1999;83:98–103
30. Waring GO 3rd, Roth AM, Ekins MB. Clinical and pathologic description of 17 cases of corneal intraepithelial neoplasia Am J Ophthalmol. 1984;97:547–59
31. Akpek EK, Polcharoen W, Chan R, Foster CS. Ocular surface neoplasia masquerading as chronic blepharoconjunctivitis Cornea. 1999;18:282–8
32. Nicholson DH, Herschler J. Intraocular extension of squamous cell carcinoma of the conjunctiva Arch Ophthalmol. 1977;95:843–6
33. Searl SS, Krigstein HJ, Albert DM, Grove AS Jr. Invasive squamous cell carcinoma with intraocular mucoepidermoid features. Conjunctival carcinoma with intraocular invasion and diphasic morphology Arch Ophthalmol. 1982;100:109–11
34. Johnson TE, Tabbara KF, Weatherhead RG, Kersten RC, Rice C, Nasr AM. Secondary squamous cell carcinoma of the orbit Arch Ophthalmol. 1997;115:75–8
35. Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B. McMahan Lecture Arch Ophthalmol. 1997;115:808–15
36. Poothullil AM, Colby KA. Topical medical therapies for ocular surface tumors Semin Ophthalmol. 2006;21:161–9
37. Majmudar PA, Epstein RJ. Antimetabolites in ocular surface neoplasia Curr Opin Ophthalmol. 1998;9:35–9
38. Sepulveda R, Pe’er J, Midena E, Seregard S, Dua HS, Singh AD. Topical chemotherapy for ocular surface squamous neoplasia: Current status Br J Ophthalmol. 2010;94:532–5
39. Shields CL, Kaliki S, Kim HJ, Al-Dahmash S, Shah SU, Lally SE, et al Interferon for ocular surface squamous neoplasia in 81 cases: Outcomes based on the American Joint Committee on Cancer classification Cornea. 2013;32:248–56
40. Karp CL, Galor A, Chhabra S, Barnes SD, Alfonso EC. Subconjunctival/perilesional recombinant interferon a2b for ocular surface squamous neoplasia: A 10-year review Ophthalmology. 2010;117:2241–6
41. Kim HJ, Shields CL, Shah SU, Kaliki S, Lally SE. Giant ocular surface squamous neoplasia managed with interferon alpha-2b as immunotherapy or immunoreduction Ophthalmology. 2012;119:938–44
42. Shields CL, Ramasubramanian A, Mellen PL, Shields JA. Conjunctival squamous cell carcinoma arising in immunosuppressed patients (organ transplant, human immunodeficiency virus infection) Ophthalmology. 2011;118:2133–7.e1
43. Sherman MD, Feldman KA, Farahmand SM, Margolis TP. Treatment of conjunctival squamous cell carcinoma with topical cidofovir Am J Ophthalmol. 2002;134:432–3
44. Shields JA, Shields CL, Freire JE, Brady LW, Komarnicky L. Plaque radiotherapy for selected orbital malignancies: Preliminary observations: The 2002 Montgomery Lecture, part 2 Ophthal Plast Reconstr Surg. 2003;19:91–5
45. Cervantes G, Rodríguez AA Jr, Leal AG. Squamous cell carcinoma of the conjunctiva: Clinicopathological features in 287 cases Can J Ophthalmol. 2002;37:14–9
46. Shields CL, Fasiuddin AF, Mashayekhi A, Shields JA. Conjunctival nevi: Clinical features and natural course in 410 consecutive patients Arch Ophthalmol. 2004;122:167–75
47. Shields CL, Demirci H, Karatza E, Shields JA. Clinical survey of 1643 melanocytic and nonmelanocytic conjunctival tumors Ophthalmology. 2004;111:1747–54
48. Shields CL, Belinsky I, Romanelli-Gobbi M, Guzman JM, Mazzuca D Jr, Green WR, et al Anterior segment optical coherence tomography of conjunctival nevus Ophthalmology. 2011;118:915–9
49. Zamir E, Mechoulam H, Micera A, Levi-Schaffer F, Pe’er J. Inflamed juvenile conjunctival naevus: Clinicopathological characterisation Br J Ophthalmol. 2002;86:28–30
50. Zimmerman LE, Sobin LH. International histological classification of tumors No. 24: Histological Typing of Tumors of the Eye and its Adnexa. 1980 Geneva World Health Organization:30
51. Jakobiec FA, Bhat P, Colby KA. Immunohistochemical studies of conjunctival nevi and melanomas Arch Ophthalmol. 2010;128:174–83
52. Shields CL, Kaliki S, Livesey M, Walker B, Garoon R, Bucci M, et al Association of ocular and oculodermal melanocytosis with the rate of uveal melanoma metastasis: Analysis of 7872 consecutive eyes JAMA Ophthalmol. 2013;131:993–1003
53. To KW, Rabinowitz SM, Friedman AH, Merker C, Cavanaugh CP. Neurofibromatosis and neural crest neoplasms: Primary acquired melanosis and malignant melanoma of the conjunctiva Surv Ophthalmol. 1989;33:373–9
54. Jakobiec FA, Folberg R, Iwamoto T. Clinicopathologic characteristics of premalignant and malignant melanocytic lesions of the conjunctiva Ophthalmology. 1989;96:147–66
55. Shields CL, Markowitz JS, Belinsky I, Schwartzstein H, George NS, Lally SE, et al Conjunctival melanoma: Outcomes based on tumor
origin in 382 consecutive cases Ophthalmology. 2011;118:389–95.e1
56. Folberg RSpencer WH. Melanocytic lesions of the conjunctiva Ophthalmic Pathology. An Atlas and Textbook. 19964th ed Philadelphia WB Saunders:125–47
57. Shields CL, Kaliki S, Al-Dahmash SA, Lally SE, Shields JA. American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes Ophthal Plast Reconstr Surg. 2012;28:313–23
58. Bajaj MS, Pushker N, Kashyap S, Balasubramanya R, Chandra M, Ghose S. Conjunctival malignant melanoma Orbit. 2003;22:47–53
59. Giblin ME, Shields JA, Shields CL, Eagle RC Jr. Primary eyelid malignant melanoma associated with primary conjunctival malignant melanoma Aust N Z J Ophthalmol. 1988;16:127–31
60. Cohen VM, Tsimpida M, Hungerford JL, Jan H, Cerio R, Moir G. Prospective study of sentinel lymph node biopsy for conjunctival melanoma Br J Ophthalmol. 2013;97:1525–9
61. Sharara NA, Alexander RA, Luthert PJ, Hungerford JL, Cree IA. Differential immunoreactivity of melanocytic lesions of the conjunctiva Histopathology. 2001;39:426–31
62. Shields JA, Shields CL, De Potter P. Surgical management of circumscribed conjunctival melanomas Ophthal Plast Reconstr Surg. 1998;14:208–15
63. Ferry AP. Pyogenic granulomas of the eye and ocular adnexa: A study of 100 cases Trans Am Ophthalmol Soc. 1989;87:327–43
64. Cameron JA, Mahmood MA. Pyogenic granulomas of the cornea Ophthalmology. 1995;102:1681–7
65. Vassallo P, Forte R, Di Mezza A, Magli A. Treatment of infantile capillary hemangioma of the eyelid with systemic propranolol Am J Ophthalmol. 2013;155:165–70.e2
66. Grossniklaus HE, Green WR, Wolff SM, Iliff NT. Hemangiopericytoma of the conjunctiva. Two cases Ophthalmology. 1986;93:265–7
67. Kurumety UR, Lustbader JM. Kaposi's sarcoma of the bulbar conjunctiva as an initial clinical manifestation of acquired immunodeficiency syndrome Arch Ophthalmol. 1995;113:978
68. Ghabrial R, Quivey JM, Dunn JP Jr, Char DH. Radiation therapy of acquired immunodeficiency syndrome-related Kaposi's sarcoma of the eyelids and conjunctiva Arch Ophthalmol. 1992;110:1423–6
69. Shields JA, De Potter P, Shields CL, Komarnicky LT. Kaposi's sarcoma of the eyelids: Response to radiotherapy Arch Ophthalmol. 1992;110:1689
70. Awdry P. Lymphangiectasia haemorrhagica conjunctivae Br J Ophthalmol. 1969;53:274–8
71. Wright JE, Sullivan TJ, Garner A, Wulc AE, Moseley IF. Orbital venous anomalies Ophthalmology. 1997;104:905–13
72. Spector JA, Zide BM. Carbon dioxide laser ablation for treatment of lymphangioma of the conjunctiva Plast Reconstr Surg. 2006;117:609–12
73. Behrendt S, Bernsmeier H, Randzio G. Fractionated beta-irradiation of a conjunctival lymphangioma Ophthalmologica. 1991;203:161–3
74. Coupland SE, Krause L, Delecluse HJ, Anagnostopoulos I, Foss HD, Hummel M, et al Lymphoproliferative lesions of the ocular adnexa. Analysis of 112 cases Ophthalmology. 1998;105:1430–41
75. Shields CL, Shields JA, Carvalho C, Rundle P, Smith AF. Conjunctival lymphoid tumors: Clinical analysis of 117 cases and relationship to systemic lymphoma Ophthalmology. 2001;108:979–84
76. Eichler MD, Fraunfelder FT. Cryotherapy for conjunctival lymphoid tumors Am J Ophthalmol. 1994;118:463–7
77. Kim HJ, Shields CL, Eagle RC Jr, Shields JA. Fibrous histiocytoma of the conjunctiva Am J Ophthalmol. 2006;142:1036–43
78. Perry HD. Isolated episcleral neurofibroma Ophthalmology. 1982;89:1095–8
79. Ferry AP. Granular cell tumor
(myoblastoma) of the palpebral conjunctiva causing pseudoepitheliomatous hyperplasia of the conjunctival epithelium Am J Ophthalmol. 1981;91:234–8
80. Giller RH, Folberg R, Keech RV, Piette WW, Sato Y. Xanthoma disseminatum. An unusual histiocytosis syndrome Am J Pediatr Hematol Oncol. 1988;10:252–7
81. Chaudhry IA, Al-Jishi Z, Shamsi FA, Riley F. Juvenile xanthogranuloma of the corneoscleral limbus: Case report and review of the literature Surv Ophthalmol. 2004;49:608–14
82. Eagle RC Jr, Penne RA, Hneleski IS Jr. Eyelid involvement in multicentric reticulohistiocytosis Ophthalmology. 1995;102:426–30
83. Pe’er J, Hidayat AA. Myxomas of the conjunctiva Am J Ophthalmol. 1986;102:80–6
84. Shields CL, Shields JA, Honavar SG, Demirci H. Clinical spectrum of primary ophthalmic rhabdomyosarcoma Ophthalmology. 2001;108:2284–92
85. Cameron JD, Wick MR. Embryonal rhabdomyosarcoma of the conjunctiva. A clinicopathologic and immunohistochemical study Arch Ophthalmol. 1986;104:1203–4
86. Polito E, Pichierri P, Loffredo A, Lasorella G. A case of primary botryoid conjunctival rhabdomyosarcoma Graefes Arch Clin Exp Ophthalmol. 2006;244:517–9
87. Bryant J. Pleomorphic lipoma of the bulbar conjunctiva Ann Ophthalmol. 1987;19:148–9
88. Krema H, El-Bolkainy N. Rapid growth of an epibulbar complex choristoma in organoid nevus syndrome Can J Ophthalmol. 2013;48:e82–5
89. Kaeser PF, Uffer S, Zografos L, Hamédani M. Tumors of the caruncle: A clinicopathologic correlation Am J Ophthalmol. 2006;142:448–55
90. Luthra CL, Doxanas MT, Green WR. Lesions of the caruncle: A clinicohistopathologic study Surv Ophthalmol. 1978;23:183–95
91. Say EA, Shields CL, Bianciotto C, Eagle RC Jr, Shields JA. Oncocytic lesions (oncocytoma) of the ocular adnexa: Report of 15 cases and review of literature Ophthal Plast Reconstr Surg. 2012;28:14–21
92. Lee SS, Robinson MR, Morris JC, Mirtsching BC, Shen D, Chan CC. Conjunctival involvement with T-cell prolymphocytic leukemia: Report of a case and review of the literature Surv Ophthalmol. 2004;49:525–36
Source of Support: Nil
Conflict of Interest: None declared.